Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
An enzyme the catalyzes the degradation of insulin, glucagon and other polypeptides. It is inhibited by bacitracin, chelating agents EDTA and 1,10-phenanthroline, and by thiol-blocking reagents such as N-ethylmaleimide, but not phosphoramidon. (Eur J Biochem 1994;223:1-5) EC 3.4.24.56.
A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.
Accumulations of extracellularly deposited AMYLOID FIBRILS within tissues.
A single-pass type I membrane protein. It is cleaved by AMYLOID PRECURSOR PROTEIN SECRETASES to produce peptides of varying amino acid lengths. A 39-42 amino acid peptide, AMYLOID BETA-PEPTIDES is a principal component of the extracellular amyloid in SENILE PLAQUES.
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
A sub-subclass of endopeptidases that depend on an ASPARTIC ACID residue for their activity.
A thermostable extracellular metalloendopeptidase containing four calcium ions. (Enzyme Nomenclature, 1992) 3.4.24.27.
ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
A serine endopeptidase isolated from Bacillus subtilis. It hydrolyzes proteins with broad specificity for peptide bonds, and a preference for a large uncharged residue in P1. It also hydrolyzes peptide amides. (From Enzyme Nomenclature, 1992) EC 3.4.21.62.
Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight.
Oligopeptides which are important in the regulation of blood pressure (VASOCONSTRICTION) and fluid homeostasis via the RENIN-ANGIOTENSIN SYSTEM. These include angiotensins derived naturally from precursor ANGIOTENSINOGEN, and those synthesized.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992) EC 3.4.15.1.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Quinuclidines are organic compounds consisting of a tricyclic structure with a three-membered ring fused to a piperidine ring, often used as building blocks in the synthesis of pharmaceuticals and bioactive molecules.
Learning the correct route through a maze to obtain reinforcement. It is used for human or animal populations. (Thesaurus of Psychological Index Terms, 6th ed)
A fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. This fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. Deposits of amyloid in the form of AMYLOID PLAQUES are associated with a variety of degenerative diseases. The amyloid structure has also been found in a number of functional proteins that are unrelated to disease.
A genus of the family RETROVIRIDAE consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3' env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species.
Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran.
The process of cleaving a chemical compound by the addition of a molecule of water.
Endopeptidases that are specific for AMYLOID PROTEIN PRECURSOR. Three secretase subtypes referred to as alpha, beta, and gamma have been identified based upon the region of amyloid protein precursor they cleave.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis.

Dynorphin A processing enzyme: tissue distribution, isolation, and characterization. (1/1042)

Limited proteolysis of the dynorphin precursor (prodynorphin) at dibasic and monobasic processing sites results in the generation of bioactive dynorphins. In the brain and neurointermediate lobe of the pituitary, prodynorphin is processed to produce alpha and beta neo endorphins, dynorphins (Dyn) A-17 and Dyn A-8, Dyn B-13, and leucine-enkephalin. The formation of Dyn A-8 from Dyn A-17 requires a monobasic cleavage between Ile and Arg. We have identified an enzymatic activity capable of processing at this monobasic site in the rat brain and neurointermediate lobe of the bovine pituitary; this enzyme is designated "dynorphin A-17 processing enzyme." In the rat brain and neurointermediate lobe, a majority of the Dyn A processing enzyme activity is membrane-associated and can be released by treatment with 1% Triton X-100. This enzyme has been purified to apparent homogeneity from the membrane extract of the neurointermediate lobe using preparative iso-electrofocussing in a granulated gel pH 3.5 to 10, FPLC using anion exchange chromatography, and non-denaturing electrophoresis. The Dyn A processing enzyme exhibits a pI of about 5.8 and a molecular mass of about 65 kDa under reducing conditions. The Dyn A processing enzyme is a metalloprotease and has a neutral pH optimum. It exhibits substantial sensitivity to metal chelating agents and thiol agents suggesting that this enzyme is a thiol-sensitive metalloprotease. Specific inhibitors of other metallopeptidases such as enkephalinase [EC 3.4.24.11], the enkephalin generating neutral endopeptidase [EC 3.4.24.15], or NRD convertase do not inhibit the Dyn A processing enzyme activity. In contrast, specific inhibitors of angiotensin converting enzyme inhibit the activity. The purified enzyme is able to process a number of neuropeptides at both monobasic and dibasic sites. These characteristics are consistent with a role for the Dyn A processing enzyme in the processing of Dyn A-17 and other neuropeptides in the brain.  (+info)

Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. (2/1042)

Previous results from our laboratory have suggested that morphine can attenuate neutrophil activation in patients with acute myocardial infarction. To elucidate if morphine preconditioning (PC) has the same effects via activation of neutrophil endopeptidase 24.11 (NEP), we measured serum levels of intercellular adhesion molecule-1 (ICAM-1), gp100MEL14 and NEP in adult Wistar rats subjected to ten different protocols (n = 10 for each) at baseline, immediately after and 2 h after morphine PC. All groups were subjected to 30 min of occlusion and 2 h of reperfusion. Similarly, morphine-induced PC was elicited by 3-min drug infusions (100 micrograms/kg) interspersed with 5-min drug-free periods before the prolonged 30-min occlusion. Infarct size (IS), as a percentage of the area at risk (AAR), was determined by triphenyltetrazolium staining. Pretreatment with morphine increased NEP activities (9.86 +/- 1.98 vs. 5.12 +/- 1.10 nmol/mg protein in control group; p < 0.001). Naloxone (mu-opioid receptor antagonist) (4.82 +/- 1.02 nmol/mg protein) and phosphoramidon (NEP inhibitor) (4.66 +/- 1.00 nmol/mg protein) inhibited morphine-activated NEP, whereas glibenclamide (ATP-sensitive potassium channel antagonist) and chelerythrine (protein kinase C inhibitor) had no effects. The ICAM-1 and gp100MEL14 of the third sampling were lowest for those with morphine PC (280 +/- 30 ng/ml and 2.2 +/- 0.7 micrograms/ml; p < 0.001), but naloxone (372 +/- 38 ng/ml and 3.8 +/- 0.9 micrograms/ml) and phosphoramidon (382 +/- 40 ng/ml and 4.2 +/- 1.1 micrograms/ml) abolished the above phenomenon. IS/AAR were definitely lowest for those with morphine PC (24 +/- 7%; p < 0.05). Morphine preconditioning increases NEP activities to attenuate shedding of gp100MEL14 and to ICAM-1 and, thus, provides myocardial protection.  (+info)

Mechanism of weight gain suppressing effect of ER-40133, an angiotensin I converting enzyme inhibitor, in growing rats. (3/1042)

Effects of ER-40133, an inhibitor of angiotensin converting enzyme (ACE), on weight gain and sodium and potassium balance were studied in growing SD male rats. Thirty-two animals (seven weeks of age) were divided into two groups; one received a standard diet containing 0.227% sodium and the other a low (0.065%) sodium diet. They were divided into four subgroups; one control group and three treated groups receiving 3, 10 or 30 mg/kg of ER-40133, by gavage, once a day for five consecutive days. Body weight gain (average of the standard and low sodium diet groups) was -32% in the 3 mg/kg group,-74% in 10 mg/kg group and -99% in 30 mg/kg group, when compared with the control group. There was a highly linear correlation between suppression of body weight gain and reduction in sodium and potassium retention for both groups of animals given the standard and low sodium diet. The reduced sodium retention, the primary effect of ACE inhibitors, accounted for about 30% of suppressed weight gain, and the reduced potassium retention, the secondary effect of sodium deficiency, could account for the rest about 70% of weight suppression by ER-40133.  (+info)

Identification of kallidin degrading enzymes in the isolated perfused rat heart. (4/1042)

Kallidin (KD) is an important vasoactive kinin whose physiological effects are strongly dependent on its degradation through local kininases. In the present study, we examined the spectrum of these enzymes and their contribution to KD degradation in isolated perfused rat hearts. By inhibiting angiotensin-converting enzyme (ACE), aminopeptidase M (APM) and neutral endopeptidase (NEP) with ramiprilat (0.25 microM), amastatin (40 microM) and phosphoramidon (1 microM), respectively, relative kininase activities were obtained. APM (44%) and ACE (35%) are the main KD degrading enzymes in rat heart; NEP (7%) plays a minor role. A participation of carboxypeptidase N (CPN) could not be found.  (+info)

Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. (5/1042)

Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate therapy for hypertension and cardiac failure. Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. We administered the NEP inhibitor ecadotril (0, 0.1, 1, 10, and 100 mg/kg/day), either alone or together with the ACE inhibitor perindopril (0.2 mg/kg/day) by 12-hourly gavage from day 2 to 28 after infarction. Ecadotril increased urine cyclic GMP and BK-(1-9) excretion. Perindopril potentiated the effect of ecadotril on urine cyclic GMP excretion. Neither perindopril nor ecadotril reduced cardiac hypertrophy when administered separately, whereas the combination of perindopril and 10 or 100 mg/kg/day ecadotril reduced heart weight/body weight ratio by 10%. Administration of ecadotril to perindopril-treated rats decreased plasma Ang-(1-7) levels, increased cardiac BK-(1-9) levels, and increased Ang II levels in plasma, kidney, aorta, and lung. These data demonstrate interactions between the effects of NEP and ACE inhibition on remodeling of the infarcted heart and on Ang and BK peptide levels. Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1-7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition.  (+info)

A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11). (6/1042)

A three-dimensional model of the 507-749 region of neutral endopeptidase-24.11 (NEP; E.C.3.4.24.11) was constructed integrating the results of secondary structure predictions and sequence homologies with the bacterial endopeptidase thermolysin. Additional data were extracted from the structure of two other metalloproteases, astacin and stromelysin. The resulting model accounts for the main biological properties of NEP and has been used to describe the environment close to the zinc atom defining the catalytic site. The analysis of several thiol inhibitors, complexed in the model active site, revealed the presence of a large hydrophobic pocket at the S1' subsite level. This is supported by the nature of the constitutive amino acids. The computed energies of bound inhibitors correspond with the relative affinities of the stereoisomers of benzofused macrocycle derivatives of thiorphan. The model could be used to facilitate the design of new NEP inhibitors, as illustrated in the paper.  (+info)

Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients. (7/1042)

Heart-transplant recipients (Htx) generally present with body fluid and sodium handling abnormalities and hypertension. To investigate whether neutral endopeptidase inhibition (NEP-I) increases endogenous atrial natriuretic peptide (ANP) and enhances natriuresis and diuresis after heart transplantation, ecadotril was given orally to 8 control subjects and 8 matched Htx, and levels of volume-regulating hormones and renal water, electrolyte, and cyclic guanosine monophosphate (cGMP) excretions were monitored for 210 minutes. Baseline plasma ANP, brain natriuretic peptide (BNP), and cGMP were elevated in Htx, but renin and aldosterone, like urinary parameters, did not differ between groups. NEP-I increased plasma ANP (Htx, 20.6+/-2.3 to 33.2+/-5.9 pmol/L, P<0.01; controls, 7.7+/-1. 2 to 10.6+/-2.6 pmol/L) and cGMP, but not BNP. Renin decreased similarly in both groups, whereas aldosterone decreased significantly only in Htx. Enhanced urinary sodium (1650+/-370% versus 450+/-150%, P=0.01), cGMP, and water excretions were observed in Htx and urinary cGMP positively correlated with natriuresis in 6 of the Htx subjects. Consistent with a normal circadian rhythm of blood pressure, without excluding a possible effect of NEP-I, mean systemic blood pressure increased similarly in both groups at the end of the study (6.9+/-2.0% versus 7.4+/-2.8% in controls and Htx). Thus, systemic hypertension, mild renal impairment, and raised plasma ANP levels are possible contributory factors in the enhanced natriuresis and diuresis with NEP-I in Htx. These results support a physiological role for the cardiac hormone after heart transplantation and suggest that long-term studies may be useful to determine the potential of NEP-I in the treatment of sodium retention and water retention after heart transplantation.  (+info)

Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. (8/1042)

BACKGROUND: Since kinins kallidin (KD) and bradykinin (BK) appear to have cardioprotective effects ranging from improved hemodynamics to antiproliferative effects, inhibition of kinin-degrading enzymes should potentiate such effects. Indeed, it is believed that this mechanism is partly responsible for the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors. In the heart, enzymes other than ACE may contribute to local degradation of kinins. The purpose of this study was to investigate which enzymes are responsible for the degradation of KD and BK in human heart tissue. METHODS AND RESULTS: Cardiac membranes were prepared from the left ventricles of normal (n=5) and failing (n=10) hearts. The patients had end-stage congestive heart failure as the result of coronary heart disease or idiopathic dilated cardiomyopathy. Heart tissue was incubated with KD or BK in the presence or absence of enzyme inhibitors. We found no difference in the enzymes responsible for kinin metabolism or their activities between normal and failing hearts. Thus KD was mostly converted into BK by the aminopeptidase M-like activity. When BK was used as substrate, it was converted into an inactive metabolite BK-(1-7) mostly (80% to 90%) by the neutral endopeptidase (NEP) activity, with ACE unexpectedly playing only a minor role. The low enzymatic activity of ACE in the cardiac membranes, compared with that of NEP, was not due to chronic ACE inhibitor therapy, because the cardiac ACE activities of patients, whether receiving ACE inhibitors or not, and of normal subjects were all equal. CONCLUSIONS: The present in vitro study shows that in human cardiac membranes, the most critical step in kinin metabolism, that is, inactivation of BK, appears to be mediated mostly by NEP. This observation suggests a role for NEP in the local control of BK concentration in heart tissue. Thus inhibition of cardiac NEP activity could be cardioprotective by elevating the local concentration of BK in the heart.  (+info)

Neprilysin (NEP), also known as membrane metallo-endopeptidase or CD10, is a type II transmembrane glycoprotein that functions as a zinc-dependent metalloprotease. It is widely expressed in various tissues, including the kidney, brain, heart, and vasculature. Neprilysin plays a crucial role in the breakdown and regulation of several endogenous bioactive peptides, such as natriuretic peptides, bradykinin, substance P, and angiotensin II. By degrading these peptides, neprilysin helps maintain cardiovascular homeostasis, modulate inflammation, and regulate neurotransmission. In the context of heart failure, neprilysin inhibitors have been developed to increase natriuretic peptide levels, promoting diuresis and vasodilation, ultimately improving cardiac function.

Thiorphan is not a medical condition or disease, but rather a synthetic medication. It is a potent inhibitor of membrane-bound metalloendopeptidases, also known as neprilysin enzymes. These enzymes are responsible for breaking down certain peptides in the body, including some hormones and neurotransmitters.

Thiorphan has been used in research to study the role of these enzymes in various physiological processes. It is also being investigated as a potential therapeutic agent for conditions such as hypertension, heart failure, and Alzheimer's disease. However, it is not currently approved for clinical use in humans.

Therefore, there is no medical definition of 'Thiorphan' as a condition or disease.

Amyloid beta-peptides (Aβ) are small protein fragments that are crucially involved in the pathogenesis of Alzheimer's disease. They are derived from a larger transmembrane protein called the amyloid precursor protein (APP) through a series of proteolytic cleavage events.

The two primary forms of Aβ peptides are Aβ40 and Aβ42, which differ in length by two amino acids. While both forms can be harmful, Aβ42 is more prone to aggregation and is considered to be the more pathogenic form. These peptides have the tendency to misfold and accumulate into oligomers, fibrils, and eventually insoluble plaques that deposit in various areas of the brain, most notably the cerebral cortex and hippocampus.

The accumulation of Aβ peptides is believed to initiate a cascade of events leading to neuroinflammation, oxidative stress, synaptic dysfunction, and neuronal death, which are all hallmarks of Alzheimer's disease. Although the exact role of Aβ in the onset and progression of Alzheimer's is still under investigation, it is widely accepted that they play a central part in the development of this debilitating neurodegenerative disorder.

I believe there might be a slight confusion in your question. There is no medical definition for "Insulysin" as it seems to be a misspelling of the term "Insulinase" or "Insulysin." I will provide you with the medical definition of Insulinase.

Insulinase, also known as Insulin-degrading enzyme (IDE), is a zinc metalloproteinase found in various tissues, including the liver, brain, and muscle. It is responsible for the intracellular degradation of insulin and other regulatory proteins like amyloid-beta peptide, glucagon, and atrial natriuretic peptide. Insulinase helps regulate blood glucose levels by controlling insulin concentrations in the body. Dysregulation of this enzyme has been implicated in diabetes, Alzheimer's disease, and other neurodegenerative disorders.

Enkephalins are naturally occurring opioid peptides in the body that bind to opiate receptors and help reduce pain and produce a sense of well-being. There are several different types of enkephalins, including Leu-enkephalin and Met-enkephalin, which differ based on their amino acid sequence.

Leucine-enkephalin (Leu-Enk) is a specific type of enkephalin that contains the amino acids tyrosine, glycine, glutamic acid, leucine, and methionine in its sequence. The Leucine-2-Alanine variant of Leu-Enk refers to a synthetic form of this peptide where the leucine at position 2 is replaced with alanine. This modification can affect the stability, activity, and pharmacological properties of the enkephalin molecule.

It's important to note that while Leu-Enk and its analogs have potential therapeutic applications in pain management, they are also subject to abuse and addiction due to their opioid properties. Therefore, their use is tightly regulated and requires careful medical supervision.

Amyloid plaque is a pathological hallmark of several degenerative diseases, including Alzheimer's disease. It refers to extracellular deposits of misfolded proteins that accumulate in various tissues and organs, but are most commonly found in the brain. The main component of these plaques is an abnormally folded form of a protein called amyloid-beta (Aβ). This protein is produced through the normal processing of the amyloid precursor protein (APP), but in amyloid plaques, it aggregates into insoluble fibrils that form the core of the plaque.

The accumulation of amyloid plaques is thought to contribute to neurodegeneration and cognitive decline in Alzheimer's disease and other related disorders. The exact mechanisms by which this occurs are not fully understood, but it is believed that the aggregation of Aβ into plaques leads to the disruption of neuronal function and viability, as well as the activation of inflammatory responses that can further damage brain tissue.

It's important to note that while amyloid plaques are a key feature of Alzheimer's disease, they are not exclusive to this condition. Amyloid plaques have also been found in other neurodegenerative disorders, as well as in some normal aging brains, although their significance in these contexts is less clear.

The Amyloid Beta-Protein Precursor (AβPP) is a type of transmembrane protein that is widely expressed in various tissues and organs, including the brain. It plays a crucial role in normal physiological processes, such as neuronal development, synaptic plasticity, and repair.

AβPP undergoes proteolytic processing by enzymes called secretases, resulting in the production of several protein fragments, including the amyloid-beta (Aβ) peptide. Aβ is a small peptide that can aggregate and form insoluble fibrils, which are the main component of amyloid plaques found in the brains of patients with Alzheimer's disease (AD).

The accumulation of Aβ plaques is believed to contribute to the neurodegeneration and cognitive decline observed in AD. Therefore, AβPP and its proteolytic processing have been the focus of extensive research aimed at understanding the pathogenesis of AD and developing potential therapies.

Alzheimer's disease is a progressive disorder that causes brain cells to waste away (degenerate) and die. It's the most common cause of dementia — a continuous decline in thinking, behavioral and social skills that disrupts a person's ability to function independently.

The early signs of the disease include forgetting recent events or conversations. As the disease progresses, a person with Alzheimer's disease will develop severe memory impairment and lose the ability to carry out everyday tasks.

Currently, there's no cure for Alzheimer's disease. However, treatments can temporarily slow the worsening of dementia symptoms and improve quality of life.

Aspartic acid endopeptidases are a type of enzyme that cleave peptide bonds within proteins. They are also known as aspartyl proteases or aspartic proteinases. These enzymes contain two catalytic aspartic acid residues in their active site, which work together to hydrolyze the peptide bond.

Aspartic acid endopeptidases play important roles in various biological processes, including protein degradation, processing, and activation. They are found in many organisms, including viruses, bacteria, fungi, plants, and animals. Some well-known examples of aspartic acid endopeptidases include pepsin, cathepsin D, and HIV protease.

Pepsin is a digestive enzyme found in the stomach that helps break down proteins in food. Cathepsin D is a lysosomal enzyme that plays a role in protein turnover and degradation within cells. HIV protease is an essential enzyme for the replication of the human immunodeficiency virus (HIV), which causes AIDS. Inhibitors of HIV protease are used as antiretroviral drugs to treat HIV infection.

Thermolysin is not a medical term per se, but it is a bacterial enzyme that is often used in biochemistry and molecular biology research. Here's the scientific or biochemical definition:

Thermolysin is a zinc metalloprotease enzyme produced by the bacteria Geobacillus stearothermophilus. It has an optimum temperature for activity at around 65°C, and it can remain active in high temperatures, which makes it useful in various industrial applications. Thermolysin is known for its ability to cleave peptide bonds, particularly those involving hydrophobic residues, making it a valuable tool in protein research and engineering.

Metalloendopeptidases are a type of enzymes that cleave peptide bonds in proteins, specifically at interior positions within the polypeptide chain. They require metal ions as cofactors for their catalytic activity, typically zinc (Zn2+) or cobalt (Co2+). These enzymes play important roles in various biological processes such as protein degradation, processing, and signaling. Examples of metalloendopeptidases include thermolysin, matrix metalloproteinases (MMPs), and neutrophil elastase.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

Angiotensin I is a decapeptide (a peptide consisting of ten amino acids) that is generated by the action of an enzyme called renin on a protein called angiotensinogen. Renin cleaves angiotensinogen to produce angiotensin I, which is then converted to angiotensin II by the action of an enzyme called angiotensin-converting enzyme (ACE).

Angiotensin II is a potent vasoconstrictor, meaning it causes blood vessels to narrow and blood pressure to increase. It also stimulates the release of aldosterone from the adrenal glands, which leads to increased sodium and water reabsorption in the kidneys, further increasing blood volume and blood pressure.

Angiotensin I itself has little biological activity, but it is an important precursor to angiotensin II, which plays a key role in regulating blood pressure and fluid balance in the body.

Protease inhibitors are a class of antiviral drugs that are used to treat infections caused by retroviruses, such as the human immunodeficiency virus (HIV), which is responsible for causing AIDS. These drugs work by blocking the activity of protease enzymes, which are necessary for the replication and multiplication of the virus within infected cells.

Protease enzymes play a crucial role in the life cycle of retroviruses by cleaving viral polyproteins into functional units that are required for the assembly of new viral particles. By inhibiting the activity of these enzymes, protease inhibitors prevent the virus from replicating and spreading to other cells, thereby slowing down the progression of the infection.

Protease inhibitors are often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS. Common examples of protease inhibitors include saquinavir, ritonavir, indinavir, and atazanavir. While these drugs have been successful in improving the outcomes of people living with HIV/AIDS, they can also cause side effects such as nausea, diarrhea, headaches, and lipodystrophy (changes in body fat distribution).

Subtilisin is not strictly a medical term, but rather a term used in biochemistry and microbiology. It refers to a group of proteolytic enzymes (proteases) that are produced by certain bacteria, particularly Bacillus subtilis. These enzymes have the ability to break down other proteins into smaller peptides or individual amino acids by cleaving specific peptide bonds.

In a medical context, subtilisin might be mentioned in relation to its use in various commercial products such as detergents and contact lens cleaning solutions, where it helps to break down protein-based stains or deposits. Additionally, subtilisins have been explored for their potential applications in therapeutics, including the treatment of certain diseases caused by protein misfolding or aggregation, like cystic fibrosis and Alzheimer's disease.

However, it is important to note that direct medical definitions of 'subtilisin' are limited, as it primarily functions within the realms of biochemistry and microbiology.

Glycopeptides are a class of antibiotics that are characterized by their complex chemical structure, which includes both peptide and carbohydrate components. These antibiotics are produced naturally by certain types of bacteria and are effective against a range of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

The glycopeptide antibiotics work by binding to the bacterial cell wall precursor, preventing the cross-linking of peptidoglycan chains that is necessary for the formation of a strong and rigid cell wall. This leads to the death of the bacteria.

Examples of glycopeptides include vancomycin, teicoplanin, and dalbavancin. While these antibiotics have been used successfully for many years, their use is often limited due to concerns about the emergence of resistance and potential toxicity.

Angiotensins are a group of hormones that play a crucial role in the body's cardiovascular system, particularly in regulating blood pressure and fluid balance. The most well-known angiotensins are Angiotensin I, Angiotensin II, and Angiotensin-(1-7).

Angiotensinogen is a protein produced mainly by the liver. When the body requires an increase in blood pressure, renin (an enzyme produced by the kidneys) cleaves angiotensinogen to form Angiotensin I. Then, another enzyme called angiotensin-converting enzyme (ACE), primarily found in the lungs, converts Angiotensin I into Angiotensin II.

Angiotensin II is a potent vasoconstrictor, causing blood vessels to narrow and increase blood pressure. It also stimulates the release of aldosterone from the adrenal glands, which leads to increased sodium reabsorption in the kidneys, further raising blood pressure and promoting fluid retention.

Angiotensin-(1-7) is a more recently discovered member of the angiotensin family. It has opposing effects to Angiotensin II, acting as a vasodilator and counterbalancing some of the negative consequences of Angiotensin II's actions.

Medications called ACE inhibitors and ARBs (angiotensin receptor blockers) are commonly used in clinical practice to target the renin-angiotensin system, lowering blood pressure and protecting against organ damage in various cardiovascular conditions.

The brain is the central organ of the nervous system, responsible for receiving and processing sensory information, regulating vital functions, and controlling behavior, movement, and cognition. It is divided into several distinct regions, each with specific functions:

1. Cerebrum: The largest part of the brain, responsible for higher cognitive functions such as thinking, learning, memory, language, and perception. It is divided into two hemispheres, each controlling the opposite side of the body.
2. Cerebellum: Located at the back of the brain, it is responsible for coordinating muscle movements, maintaining balance, and fine-tuning motor skills.
3. Brainstem: Connects the cerebrum and cerebellum to the spinal cord, controlling vital functions such as breathing, heart rate, and blood pressure. It also serves as a relay center for sensory information and motor commands between the brain and the rest of the body.
4. Diencephalon: A region that includes the thalamus (a major sensory relay station) and hypothalamus (regulates hormones, temperature, hunger, thirst, and sleep).
5. Limbic system: A group of structures involved in emotional processing, memory formation, and motivation, including the hippocampus, amygdala, and cingulate gyrus.

The brain is composed of billions of interconnected neurons that communicate through electrical and chemical signals. It is protected by the skull and surrounded by three layers of membranes called meninges, as well as cerebrospinal fluid that provides cushioning and nutrients.

Peptidyl-dipeptidase A is more commonly known as angiotensin-converting enzyme (ACE). It is a key enzyme in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance.

ACE is a membrane-bound enzyme found primarily in the lungs, but also in other tissues such as the heart, kidneys, and blood vessels. It plays a crucial role in converting the inactive decapeptide angiotensin I into the potent vasoconstrictor octapeptide angiotensin II, which constricts blood vessels and increases blood pressure.

ACE also degrades the peptide bradykinin, which is involved in the regulation of blood flow and vascular permeability. By breaking down bradykinin, ACE helps to counteract its vasodilatory effects, thereby maintaining blood pressure homeostasis.

Inhibitors of ACE are widely used as medications for the treatment of hypertension, heart failure, and diabetic kidney disease, among other conditions. These drugs work by blocking the action of ACE, leading to decreased levels of angiotensin II and increased levels of bradykinin, which results in vasodilation, reduced blood pressure, and improved cardiovascular function.

Transgenic mice are genetically modified rodents that have incorporated foreign DNA (exogenous DNA) into their own genome. This is typically done through the use of recombinant DNA technology, where a specific gene or genetic sequence of interest is isolated and then introduced into the mouse embryo. The resulting transgenic mice can then express the protein encoded by the foreign gene, allowing researchers to study its function in a living organism.

The process of creating transgenic mice usually involves microinjecting the exogenous DNA into the pronucleus of a fertilized egg, which is then implanted into a surrogate mother. The offspring that result from this procedure are screened for the presence of the foreign DNA, and those that carry the desired genetic modification are used to establish a transgenic mouse line.

Transgenic mice have been widely used in biomedical research to model human diseases, study gene function, and test new therapies. They provide a valuable tool for understanding complex biological processes and developing new treatments for a variety of medical conditions.

Quinuclidines are a class of organic compounds that contain a unique cage-like structure consisting of a tetrahydrofuran ring fused to a piperidine ring. The name "quinuclidine" is derived from the Latin word "quinque," meaning five, and "clidis," meaning key or bar, which refers to the five-membered ring system that forms the core of these compounds.

Quinuclidines have a variety of biological activities and are used in pharmaceuticals as well as agrochemicals. Some quinuclidine derivatives have been found to exhibit anti-inflammatory, antiviral, and anticancer properties. They can also act as inhibitors of various enzymes and receptors, making them useful tools for studying biological systems and developing new drugs.

It is worth noting that quinuclidines are not typically used in medical diagnosis or treatment, but rather serve as building blocks for the development of new pharmaceutical compounds.

Maze learning is not a medical term per se, but it is a concept that is often used in the field of neuroscience and psychology. It refers to the process by which an animal or human learns to navigate through a complex environment, such as a maze, in order to find its way to a goal or target.

Maze learning involves several cognitive processes, including spatial memory, learning, and problem-solving. As animals or humans navigate through the maze, they encode information about the location of the goal and the various landmarks within the environment. This information is then used to form a cognitive map that allows them to navigate more efficiently in subsequent trials.

Maze learning has been widely used as a tool for studying learning and memory processes in both animals and humans. For example, researchers may use maze learning tasks to investigate the effects of brain damage or disease on cognitive function, or to evaluate the efficacy of various drugs or interventions for improving cognitive performance.

Amyloid is a term used in medicine to describe abnormally folded protein deposits that can accumulate in various tissues and organs of the body. These misfolded proteins can form aggregates known as amyloid fibrils, which have a characteristic beta-pleated sheet structure. Amyloid deposits can be composed of different types of proteins, depending on the specific disease associated with the deposit.

In some cases, amyloid deposits can cause damage to organs and tissues, leading to various clinical symptoms. Some examples of diseases associated with amyloidosis include Alzheimer's disease (where amyloid-beta protein accumulates in the brain), systemic amyloidosis (where amyloid fibrils deposit in various organs such as the heart, kidneys, and liver), and type 2 diabetes (where amyloid deposits form in the pancreas).

It's important to note that not all amyloid deposits are harmful or associated with disease. However, when they do cause problems, treatment typically involves managing the underlying condition that is leading to the abnormal protein accumulation.

A lentivirus is a type of slow-acting retrovirus that can cause chronic diseases and cancers. The term "lentivirus" comes from the Latin word "lentus," which means slow. Lentiviruses are characterized by their ability to establish a persistent infection, during which they continuously produce new viral particles.

Lentiviruses have a complex genome that includes several accessory genes, in addition to the typical gag, pol, and env genes found in all retroviruses. These accessory genes play important roles in regulating the virus's replication cycle and evading the host's immune response.

One of the most well-known lentiviruses is the human immunodeficiency virus (HIV), which causes AIDS. Other examples include the feline immunodeficiency virus (FIV) and the simian immunodeficiency virus (SIV). Lentiviruses have also been used as vectors for gene therapy, as they can efficiently introduce new genes into both dividing and non-dividing cells.

Furans are not a medical term, but a class of organic compounds that contain a four-membered ring with four atoms, usually carbon and oxygen. They can be found in some foods and have been used in the production of certain industrial chemicals. Some furan derivatives have been identified as potentially toxic or carcinogenic, but the effects of exposure to these substances depend on various factors such as the level and duration of exposure.

In a medical context, furans may be mentioned in relation to environmental exposures, food safety, or occupational health. For example, some studies have suggested that high levels of exposure to certain furan compounds may increase the risk of liver damage or cancer. However, more research is needed to fully understand the potential health effects of these substances.

It's worth noting that furans are not a specific medical condition or diagnosis, but rather a class of chemical compounds with potential health implications. If you have concerns about exposure to furans or other environmental chemicals, it's best to consult with a healthcare professional for personalized advice and recommendations.

Hydrolysis is a chemical process, not a medical one. However, it is relevant to medicine and biology.

Hydrolysis is the breakdown of a chemical compound due to its reaction with water, often resulting in the formation of two or more simpler compounds. In the context of physiology and medicine, hydrolysis is a crucial process in various biological reactions, such as the digestion of food molecules like proteins, carbohydrates, and fats. Enzymes called hydrolases catalyze these hydrolysis reactions to speed up the breakdown process in the body.

Amyloid precursor protein (APP) secretases are enzymes that are responsible for cleaving the amyloid precursor protein into various smaller proteins. There are two types of APP secretases: α-secretase and β-secretase.

α-Secretase is a member of the ADAM (a disintegrin and metalloproteinase) family, specifically ADAM10 and ADAM17. When APP is cleaved by α-secretase, it produces a large ectodomain called sAPPα and a membrane-bound C-terminal fragment called C83. This pathway is known as the non-amyloidogenic pathway because it prevents the formation of amyloid-β (Aβ) peptides, which are associated with Alzheimer's disease.

β-Secretase, also known as β-site APP cleaving enzyme 1 (BACE1), is a type II transmembrane aspartic protease. When APP is cleaved by β-secretase, it produces a large ectodomain called sAPPβ and a membrane-bound C-terminal fragment called C99. Subsequently, C99 is further cleaved by γ-secretase to generate Aβ peptides, including the highly neurotoxic Aβ42. This pathway is known as the amyloidogenic pathway because it leads to the formation of Aβ peptides and the development of Alzheimer's disease.

Therefore, APP secretases play a crucial role in the regulation of APP processing and have been the focus of extensive research in the context of Alzheimer's disease and other neurodegenerative disorders.

Gene expression regulation, enzymologic refers to the biochemical processes and mechanisms that control the transcription and translation of specific genes into functional proteins or enzymes. This regulation is achieved through various enzymatic activities that can either activate or repress gene expression at different levels, such as chromatin remodeling, transcription factor activation, mRNA processing, and protein degradation.

Enzymologic regulation of gene expression involves the action of specific enzymes that catalyze chemical reactions involved in these processes. For example, histone-modifying enzymes can alter the structure of chromatin to make genes more or less accessible for transcription, while RNA polymerase and its associated factors are responsible for transcribing DNA into mRNA. Additionally, various enzymes are involved in post-transcriptional modifications of mRNA, such as splicing, capping, and tailing, which can affect the stability and translation of the transcript.

Overall, the enzymologic regulation of gene expression is a complex and dynamic process that allows cells to respond to changes in their environment and maintain proper physiological function.

... the relationship between neprilysin expression and carcinogenesis remains obscure. In cancer biomarker studies, the neprilysin ... Neprilysin is expressed in a wide variety of tissues and is particularly abundant in kidney. It is also a common acute ... Because neprilysin is thought to be the rate-limiting step in amyloid beta degradation, it has been considered a potential ... Declining neprilysin activity with increasing age may also be explained by oxidative damage, known to be a causative factor in ...
Works best at pH 8. Neprilysin "endopeptidase". Merriam-Webster. Archived from the original on 21 December 2016. Retrieved 18 ...
Campbell DJ (2018-09-19). "Neprilysin Inhibitors and Bradykinin". Frontiers in Medicine. 5: 257. doi:10.3389/fmed.2018.00257. ... neprilysin, NEP2, aminopeptidase P (APP), carboxypeptidase N (CPN, kininase I), Carboxypeptidase M, Neutral endopeptidase 24.15 ...
Action of neprilysin on angiotensin I or angiotensin II. Action of prolyl endopeptidase on angiotensin I. Action of ACE on ... by the actions of neprilysin (NEP) and thimet oligopeptidase (TOP) enzymes. Also, Ang II can be hydrolyzed into Ang (1-7) ... angiotensin 1-9. Action of neprilysin on angiotensin 1-9. Action of ACE2 on angiotensin II. Ang (1-7) has been shown to have ...
In addition, neprilysin degrades a variety of peptides including bradykinin, an inflammatory mediator. The large scale ... September 2014). "Angiotensin-neprilysin inhibition versus enalapril in heart failure". The New England Journal of Medicine. ... Sacubitrilat inhibits the enzyme neprilysin, which is responsible for the degradation of atrial and brain natriuretic peptide, ... April 2010). "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor ( ...
Neutral endopeptidase (NEP) also known as neprilysin is the enzyme that metabolizes natriuretic peptides. Several inhibitors of ... "Angiotensin-neprilysin inhibition versus enalapril in heart failure". The New England Journal of Medicine. 371 (11): 993-1004. ...
Pardossi-Piquard R, Dunys J, Yu G, St George-Hyslop P, Alves da Costa C, Checler F (May 2006). "Neprilysin activity and ... Nicastrin has also been identified as a regulator of neprilysin, an enzyme involved in the degradation of amyloid beta fragment ...
Blockade of neprilysin, a protease known to degrade members of the natriuretic peptide family, has also been suggested as a ... Dual administration of neprilysin inhibitors and angiotensin receptor blockers has been shown to be advantageous to ACE ... "Angiotensin-neprilysin inhibition versus enalapril in heart failure". The New England Journal of Medicine. 371 (11): 993-1004. ... "Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure". The New England Journal of Medicine. 380 (6): 539-548 ...
September 2014). "Angiotensin-neprilysin inhibition versus enalapril in heart failure". The New England Journal of Medicine. ... Fala L (September 2015). "Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA ...
11 September 2014). "Angiotensin-neprilysin inhibition versus enalapril in heart failure". The New England Journal of Medicine ...
Oefner C; D'Arcy A; Hennig M; Winkler FK; Dale GE (February 2000). "Structure of human neutral endopeptidase (Neprilysin) ... Candoxatril is the orally active prodrug of candoxatrilat (UK-73967). Human neutral endopeptidase (neprilysin) as the neutral ... neprilysin family, clan MA(E)) the gluzincins a faint but significant structural relationship of the metzincins to the ...
The peptidase M13 family believed to activate or inactivate oligopeptide (pro)-hormones such as opioid peptides, neprilysin is ... Turner AJ, Isaac RE, Coates D (March 2001). "The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function ...
2 Nov 2014 2. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF Investigators); NEJM.org, ... and Angiotensin-Neprilysin Inhibitor LCZ969.: 120 The angioedema appears to be dose dependent as it may resolve with decreased ...
... and neprilysin". Cellular and Molecular Life Sciences. 65 (16): 2574-85. doi:10.1007/s00018-008-8112-4. PMC 2756532. PMID ...
It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin). "International Nonproprietary ...
It inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in ... and neprilysin (neutral endopeptidase), both of these enzymes are responsible for the metabolism of bradykinin which causes ...
"Entrez Gene: Membrane metallo-endopeptidase-like 1". Whyteside AR, Turner AJ (July 2008). "Human neprilysin-2 (NEP2) and NEP ...
2007). "On the role of endothelin-converting enzyme 1 (ECE-1) and neprilysin in human breast cancer". Breast Cancer Res. Treat ...
The encoded protein contains sequence and structural similarity to members of the neprilysin (M13) family of zinc ...
In the mid-1990s, Richards pioneered human clinical studies of neprilysin inhibition, important in metabolism of the NPs. His ...
Repressive hypermethylation caused by amyloid-beta has been observed at the promoter of NEP, the gene for neprilysin, which is ... on global DNA and neprilysin genes in murine cerebral endothelial cells". primary. Biochemical and Biophysical Research ...
... s will lose their activity when degraded by the enzyme neprilysin which is found on the plasma membrane. The ...
November 2008). "Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral ... it was shown that Aβ deposition and plaque formation can be reduced by sustained expression of the neprilysin (an endopeptidase ...
... may refer to: Neprilysin, an enzyme Meprin A, an enzyme This disambiguation page lists articles associated with ...
... and neprilysin (EC 3.4.24.11)". Analytical Biochemistry. 292 (2): 257-65. doi:10.1006/abio.2001.5083. PMID 11355859. Rioli V, ...
The angiotensin receptor-neprilysin inhibitors (ARNI) sacubitril/valsartan is recommended as first choice of RAS inhibitors in ... Quadruple medical therapy using a combination of angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers, ... or angiotensin receptor-neprilysin inhibitors, along with beta blockers, mineralocorticoid receptor antagonists and SGLT2 ...
Some examples of endopeptidase inhibitors include the following: Neprilysin inhibitors Selective neprilysin inhibitors ... inhibitor of neprilysin and thermolysin; also inhibits ECE RB-101 - also inhibits aminopeptidase N (APN) (an exopeptidase) ... active metabolite of racecadotril UK-414,495 Non-selective neprilysin inhibitors Aladotril - also inhibits angiotensin ...
... neprilysin, EC 3.4.24.11), had been described, at the end of the 1960s, and in 1973, respectively. Short 'oligopeptides', ... angiotensin-converting enzyme and neprilysin). Thus, the redox state of the intracellular environment very likely modulates the ...
He has clinically developed racecadotril (Tiorfan®), a neprilysin ("enkephalinase") inhibitor, the first selective intestinal ...
... enzymatic degradation by neprilysin or insulysin (3) cleared by way of the blood-brain barrier or (4) drained along ...
... the relationship between neprilysin expression and carcinogenesis remains obscure. In cancer biomarker studies, the neprilysin ... Neprilysin is expressed in a wide variety of tissues and is particularly abundant in kidney. It is also a common acute ... Because neprilysin is thought to be the rate-limiting step in amyloid beta degradation, it has been considered a potential ... Declining neprilysin activity with increasing age may also be explained by oxidative damage, known to be a causative factor in ...
... 27 Aug 2022 ... As neprilysin is postulated to have a role in the degradation of amyloid β in the brain, sacubitril could theoretically ... The neprilysin inhibitor, sacubitril, is used in combination with valsartan for the treatment of heart failure (HF) with ... amyloid β clearance pathways exist in the brain that would likely compensate for any decreased clearance related to neprilysin ...
Tags: Angiotensin Receptor Neprilysin Inhibitor, enalapril, Milton Packer, Novartis. March 31st, 2014. Early Success for Novel ... Posts Tagged Angiotensin Receptor Neprilysin Inhibitor. RSS. September 29th, 2014. The Implications of PARADIGM-HF for ... Tags: ACE inhibitors, Angiotensin Receptor Neprilysin Inhibitor, heart failure, PARADIGM-HF. August 28th, 2014. Predicting ... Tags: ACE inhibitors, Angiotensin Receptor Neprilysin Inhibitor, ECC, heart failure, LCZ696, Novartis, PARADIGM-HF, ...
neprilysin 2, rat EC 3.4.24.11 *Neprilysin. Neuroscience 2003;118(3):627-39 endopeptidase 24.11, Bombyx EC 3.4.24.- *Neprilysin ... neprilysin 2, mouse EC 3.4.24.11 *Neprilysin. Mol Cell Biochem 2008 Jun;313(1-2):103-11 AR60 compound 0 *Phosphinic Acids ... Neprilysin. DNA Cell Biol 2001 Aug;20(8):493-8 SLV 306 0 *Benzazepines Neprilysin/antagonists & inhibitors. Trends Pharmacol ... Dipeptides Neprilysin/antagonists & inhibitors. Pharma Action Protease Inhibitors J Clin Invest 1990;85(1):170 3-. (N- ...
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial * ...
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. ...
Neprilysin Inhibitor. Patients taking concomitant neprilysin inhibitors (e.g., sacubitril) may be at increased risk for ...
Synthesized as a membrane-bound protein, the neprilysin ectodomain is released into the extracellular domain after it has been ... Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates ... AHU-377 Hemicalcium is a potent Neprilysin inhibitor with an IC50 of 5 nM.. ... HIF HIV Integrase HMGCR HSP Hydroxylase IDH IDO Lipase Lipoxygenase LXR MAO Mineralocorticoid Receptor NAE NAMPT Neprilysin ...
Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. RECENT ... Sacubitril/valsartan is the first Angiotensin receptor-neprilysin inhibitor (ARNI) to be produced and has been shown to ... Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. RECENT ... Sacubitril/valsartan is the first Angiotensin receptor-neprilysin inhibitor (ARNI) to be produced and has been shown to ...
A new drug class called angiotensin receptor-neprilysin inhibitors (ARNIs) combines an ARB drug with a new type of drug. ...
Neprilysin Inhibitors. Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. (see WARNINGS ... VASOTEC is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer VASOTEC within 36 ... therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS). ... hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS). ...
This assay has high sensitivity and excellent specificity for Rat Neprilysin. No significant cross-reactivity or Rat Neprilysin ... Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates ... ELISA: Rat Neprilysin ELISA Kit (Colorimetric) These standard curves are provided for demonstration only. A standard curve ... Neprilysin , also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 ( ...
Neprilysin inhibition results in hyperglucagonemia and this may explain the worsen glucose tolerance observed in this study. ... Neprilysin inhibition results in hyperglucagonemia and this may explain the worsen glucose tolerance observed in this study. ... Neprilysin inhibition results in hyperglucagonemia and this may explain the worsen glucose tolerance observed in this study. ... Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. Research output: Contribution to ...
ARNIs combine ARBs and neprilysin inhibitors. Neprilysin is an enzyme that degrades. natriuretic peptides and other mediators ...
Home , Hydrolase Inhibitors/Modulators , Neprilysin (MME) Inhibitor Neprilysin (MME) Inhibitor Neprilysin (MME) Inhibitor ...
Neprilysin Inhibitors. Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema (see WARNINGS ... Enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril ... therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS). ... maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS, Head and Neck ...
Angiotensin Receptor-Neprilysin Inhibitors (ARNi) Class Summary. Angiotensin receptor-neprilysin inhibitor (ARNI) combinations ... Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11. 371 (11):993-1004. [QxMD ... Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019 Oct 24. 381 (17):1609- ... The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind ...
Neprilysin (NEP), a neutral endopeptidase, is one of the major Aβ-degrading enzymes in the brain. Activation of NEP is a ... Neprilysin (NEP), a neutral endopeptidase, is one of the major Aβ-degrading enzymes in the brain. Activation of NEP is a ... Localization of mature neprilysin in lipid rafts. / Sato, Kimihiko; Tanabe, Chiaki; Yonemura, Yoji et al. In: Journal of ... Neprilysin (NEP), a neutral endopeptidase, is one of the major Aβ-degrading enzymes in the brain. Activation of NEP is a ...
7.7 Neprilysin Inhibitor. Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema [see ... 7.7 Neprilysin Inhibitor 7.8 Gold 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Pediatric Use 8.4 Geriatric Use ... Benazepril hydrochloride tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not ... therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.7)] . ...
Neprilysin activity at the BLA-Im synapse is upregulated during opioid withdrawal. A, Neprilysin (NEP) is co-localized with met ... The reliance of neprilysin activity on adenylyl cyclase/PKA has several important implications. First, that neprilysin activity ... Neprilysin upregulation occurs through a PKA-dependent mechanism. Having demonstrated that neprilysin control of endogenous ... B, Bar chart showing the proportion of nociception inhibition prevented by neprilysin activity. Neprilysin activity was ...
Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation *Youzheng Dong ... Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation *Youzheng Dong ...
Neprilysin in complex with the inhibitor (R)-4-(1-carboxy-3-(3-chlorobiphenyl-4-yl)propan-2-ylamino)-4-oxobutanoic acid ... Neprilysin in complex with the inhibitor (R)-4-(1-carboxy-3-(3-chlorobiphenyl-4-yl)propan-2-ylamino)-4-oxobutanoic acid ... Kawanami, T. et al., Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors. Acs ...
Enzyme activity evaluation and tissue distribution of Neprilysin in heart failure. Session: Poster Session 2 - Basic Science - ...
Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia Best source ...
NEPRILYSIN IS NOT INVOLVED IN REGENERATION AND RE-MYELINATION AFTER NERVE INJURY ... NEPRILYSIN IS NOT INVOLVED IN REGENERATION AND RE-MYELINATION AFTER NERVE INJURY ...
Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models BIBLIOGRAPHIC ... This study genetically-modified NSCs to stably express and secrete the Aβ-degrading enzyme, neprilysin (sNEP). To determine ... After three months, stem cell engraftment, neprilysin expression, and AD pathology were examined. Results reveal that stem cell ... 2008) Long-term neprilysin gene transfer is associated with reduced levels of … ...
Neprilysin activity and expression are controlled by nicastrin. R. Pardossi-Piquard, J. Dunys, G. Yu, P. St. George-Hyslop, C. ... Dive into the research topics of Neprilysin activity and expression are controlled by nicastrin. Together they form a unique ...
Role of neprilysin in airway inflammation induced by diesel exhaust emissions.. Simon S. Wong, Nina N. Sun, Cynthia D. Fastje, ... Dive into the research topics of Role of neprilysin in airway inflammation induced by diesel exhaust emissions.. Together ...
Neprilysin (NEP) is a sort II membrane metalloproteinase that cleaves physiologically. Neprilysin (NEP) is a sort II membrane ... Launch Natural endopeptidase 24.11 (NEP, neprilysin, Compact disc10) is really a zinc metallopeptidase which has comprehensive ...
Neprilysin; Neurodegeneration; Nrf2; Opioid; Oxidative stress; Oxymetholone; PET imaging; Performance-enhancing drugs; Polydrug ...
  • The neprilysin inhibitor, sacubitril, is used in combination with valsartan for the treatment of heart failure (HF) with reduced ejection fraction. (escardio.org)
  • AHU-377 Hemicalcium is a potent Neprilysin inhibitor with an IC50 of 5 nM. (csnpharm.cn)
  • Sacubitril/valsartan is the first Angiotensin receptor-neprilysin inhibitor (ARNI) to be produced and has been shown to substantially improve cardiovascular outcomes in heart failure and delay progression of kidney disease in this population. (ox.ac.uk)
  • abstract = 'AIMS: Sacubitril/valsartan is a neprilysin-inhibitor/angiotensin II receptor blocker used for treatment of heart failure. (ku.dk)
  • Sacubitril/valsartan (Entresto), an angiotensin receptor-neprilysin inhibitor (ARNI), was approved by the FDA in July 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with congestive heart failure (New York Heart Association [NYHA] class II-IV) and reduced ejection fraction. (medscape.com)
  • How Black patients with ADHF respond to sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, is unclear. (kaiserpermanente.org)
  • Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection. (bvsalud.org)
  • Angiotensin receptor - neprilysin inhibitor (ARNI) is a promising therapeutic candidate for both diseases . (bvsalud.org)
  • The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. (qxmd.com)
  • We assessed the efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), in patients with this disorder. (qxmd.com)
  • Sacubitril is a neprilysin inhibitor that is now coupled to a new partner (an ARB), hoping to shed a toxic past. (medscape.com)
  • This trial tested whether a neprilysin inhibitor coupled to valsartan provided more benefit than enalapril in patients with heart failure. (medscape.com)
  • That is why it is important to add neprilysin inhibition to either an ACE-inhibitor or an ARB. (medscape.com)
  • LCZ696 is a combination of the neprilysin inhibitor sacubitril and valsartan. (medscape.com)
  • Colucci, Wilson S. Angiotensin II receptor blocker and neprilysin inhibitor therapy in heart failure due to systolic dysfunction. (bvs.br)
  • http://www.uptodate.com/contents/angiotensin-ii-receptor-blocker-and-neprilysin-inhibitor-therapy-in-heart-failure-due-to-systolic-dysfunction?source=search_result&search=ANGIOTENSIN+II+RECEPTOR+BLOCKERS+IN+HEART+FAILURE+DUE+TO+SYSTOLIC+DYSFUNCTION%3A+THERAPEUTIC+USE&selectedTitle=2~150 Acesso em: 8 dez 2014. (bvs.br)
  • Prof. McMurray comments, "The concern about increased cerebral amyloid β deposition with sacubitril/valsartan was always hypothetical and multiple enzymatic and other amyloid β clearance pathways exist in the brain that would likely compensate for any decreased clearance related to neprilysin inhibition. (escardio.org)
  • taleNeprilysin and Neprilysin inhibition in chronic kidney disease. (ox.ac.uk)
  • Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. (ox.ac.uk)
  • Neprilysin inhibition results in hyperglucagonemia and this may explain the worsen glucose tolerance observed in this study. (ku.dk)
  • Chronic kidney disease, heart failure and neprilysin inhibition. (nih.gov)
  • How will tolvaptan hold up to an old renin-angiotensin system behemoth with shiny new neprilysin inhibition rims? (medscape.com)
  • So, the net effect of neprilysin inhibition is difficult to predict. (medscape.com)
  • The inhibition of neprilysin alone (in the form of candoxatril) was studied back in 1993 and reported in the journal Clinical Science . (medscape.com)
  • Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF. (who.int)
  • A new drug class called angiotensin receptor-neprilysin inhibitors (ARNI's) combines an ARB drug with a new type of drug. (medlineplus.gov)
  • ARNIs combine ARBs and neprilysin inhibitors. (medicalnewstoday.com)
  • Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors. (expasy.org)
  • Hence, there is much interest in using inhibitors of neprilysin in CKD . (medscape.com)
  • As neprilysin is postulated to have a role in the degradation of amyloid β in the brain, sacubitril could theoretically increase amyloid β plaque deposition and potentially increase the risk of Alzheimer's disease. (escardio.org)
  • Neprilysin (/ˌnɛprɪˈlaɪsɪn/), also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 (CD10), and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene. (wikipedia.org)
  • Neprilysin (NEP), a neutral endopeptidase, is one of the major Aβ-degrading enzymes in the brain. (elsevierpure.com)
  • the former molecule belongs to a family of agents that are the current standard of care for HF and the latter molecule is a novel agent which inhibits neprilysin - a neutral endopeptidase found in human plasma which alters neurohumoral responses. (viamedica.pl)
  • Neprilysin is an enzyme that degrades natriuretic peptides and other mediators of heart failure. (medicalnewstoday.com)
  • This study genetically-modified NSCs to stably express and secrete the Aβ-degrading enzyme, neprilysin (sNEP). (nih.gov)
  • Neprilysin (NPL), the rate-limiting enzyme for amyloid beta peptide (AβP), appears to play a crucial role in the pathogenesis of Alzheimer's disease (AD). (northwestern.edu)
  • Cell-surface expression of the major Aβ degrading enzyme, neprilysin, depends on phosphorylation by MEK and dephosphorylation by protein phosphatase 1a. (riken.jp)
  • IL-33 does so by inducing an enzyme called neprilysin, which is known to degrade soluble amyloid. (gla.ac.uk)
  • Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. (wikipedia.org)
  • Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. (ox.ac.uk)
  • Altogether, we observed heterozygous rare loss-of-function and missense mutations in MME encoding the metalloprotease neprilysin in 19 index case subjects diagnosed with axonal polyneuropathies or neurodegenerative conditions involving the peripheral nervous system. (ox.ac.uk)
  • Neprilysin is a circulating and membrane-bound metalloprotease that cleaves peptides. (medscape.com)
  • Synthesized as a membrane-bound protein, the neprilysin ectodomain is released into the extracellular domain after it has been transported from the Golgi apparatus to the cell surface. (wikipedia.org)
  • In cancer biomarker studies, the neprilysin gene is often referred to as CD10 or CALLA. (wikipedia.org)
  • Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. (reference.md)
  • Neprilysin is also associated with other biochemical processes, and is particularly highly expressed in kidney and lung tissues. (wikipedia.org)
  • Neprilysin-deficient knockout mice show both Alzheimer's-like behavioral impairment and amyloid-beta deposition in the brain, providing strong evidence for the protein's association with the Alzheimer's disease process. (wikipedia.org)
  • Although neprilysin is known to degrade β-amyloid, we observed no increased amyloid deposition or increased incidence of dementia in individuals with MME mutations. (ox.ac.uk)
  • Neprilysin (NEP) is a sort II membrane metalloproteinase that cleaves physiologically dynamic peptides on the cell surface area thus regulating the neighborhood concentration of the peptides designed for receptor binding and indication transduction. (opioid-receptors.com)
  • Circulating neprilysin and corin concentrations, which correlate with outcomes, could possibly be assessed to guide heart failure therapy. (the-hospitalist.org)
  • We also found that MME mutations resulted in strongly decreased tissue availability of neprilysin and impaired enzymatic activity. (ox.ac.uk)
  • in other types, most notably lung cancers, neprilysin is downregulated, and thus unable to modulate the pro-growth autocrine signaling of cancer cells via secreted peptides such as mammalian homologs related to bombesin. (wikipedia.org)
  • The toxic past was a drug called omapatrilat, which has combined ACE and neprilysin inhibitory effects that initially showed promise in heart failure until angioedema stole the show and proved too hazardous. (medscape.com)
  • however, the relationship between neprilysin expression and carcinogenesis remains obscure. (wikipedia.org)
  • Detection of MME mutations is expected to increase the diagnostic yield in late-onset polyneuropathies, and it will be tempting to explore whether substances that can elevate neprilysin activity could be a rational option for treatment. (ox.ac.uk)
  • Metabolic regulation of brain Aβ by neprilysin. (riken.jp)
  • higher levels of inappropriately oxidized neprilysin have been found in Alzheimer's patients compared to cognitively normal elderly people. (wikipedia.org)
  • Role of neprilysin in airway inflammation induced by diesel exhaust emissions. (arizona.edu)
  • Dive into the research topics of 'Role of neprilysin in airway inflammation induced by diesel exhaust emissions. (arizona.edu)
  • Transcatheter edge-to-edge repair (TEER) should be considered in patients with heart failure and secondary mitral regurgitation (MR). Angiotensin receptor-neprilysin inhibitors (ARNIs) have been demonstrated to improve prognosis in heart failure. (revespcardiol.org)
  • A new drug class called angiotensin receptor-neprilysin inhibitors (ARNI's) combines an ARB drug with a new type of drug. (medlineplus.gov)
  • Neprilysin has an essential role in regulating fluid balance and vascular resistance, and neprilysin inhibitors have shown beneficial effects in patients with heart failure. (biomedcentral.com)
  • Angiotensin receptor/neprilysin inhibitors (ARNIs) are a newer combination drug for the treatment of heart failure. (msdmanuals.com)
  • They include an ARB and a new class of drug, neprilysin inhibitors. (msdmanuals.com)
  • It belongs to the angiotensin-neprilysin inhibitors class of drugs. (yashodahospitals.com)
  • Neprilysin (/ˌnɛprɪˈlaɪsɪn/), also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 (CD10), and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene. (wikipedia.org)
  • Furthermore, gene-based analysis provided significant evidence of association (P = 2.5 × 10−5) for a rare potentially damaging missense variant in the MME gene, encoding for the membrane metallo-endopeptidase neprilysin. (unimore.it)
  • Activating AhR alleviates cognitive deficits of Alzheimer ' s disease model mice by upregulating endogenous Aβ catabolic enzyme Neprilysin . (nih.gov)
  • That neprilysin (NEP) is a major Aβ peptide-degrading enzyme in vivo is shown by higher Aβ peptide levels in the brain of an NEP knockout mouse. (nih.gov)
  • Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Neprilysin (NEP) in serum, plasma and other biological fluids. (1elisakits.com)
  • Neprilysin is an enzyme involved in the breakdown of certain substances (peptides) that signal the body to excrete sodium. (msdmanuals.com)
  • Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2. (cdc.gov)
  • higher levels of inappropriately oxidized neprilysin have been found in Alzheimer's patients compared to cognitively normal elderly people. (wikipedia.org)
  • These findings demonstrate that peripherally expressed neprilysin, and likely other Abeta-degrading enzymes, has the potential to be utilized as a therapeutic approach to prevent and treat Alzheimer's disease and suggest that this approach should be explored further. (nih.gov)
  • Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. (wikipedia.org)
  • Neprilysin (NEP) is a neutral endopeptidase, a zinc-dependent metalloprotease that inactivates several peptide hormones. (anaspec.com)
  • in other types, most notably lung cancers, neprilysin is downregulated, and thus unable to modulate the pro-growth autocrine signaling of cancer cells via secreted peptides such as mammalian homologs related to bombesin. (wikipedia.org)
  • The aim of this study was to assess the prognostic value of soluble neprilysin (sNEP) levels in patients with ischemic heart disease. (biomedcentral.com)
  • However, the potential predictive value of neprilysin levels as a biomarker for cardiovascular risk remains unclear. (biomedcentral.com)
  • Therefore, efforts have been made to inhibit neprilysin as a treatment target for heart failure (HF), and recent clinical trials have obtained remarkable results. (biomedcentral.com)
  • Description: A sandwich ELISA kit for detection of Neprilysin from Mouse in samples from blood, serum, plasma, cell culture fluid and other biological fluids. (1elisakits.com)
  • Description: A sandwich quantitative ELISA assay kit for detection of Rat Neprilysin (NEP) in samples from serum, plasma, tissue homogenates or other biological fluids. (1elisakits.com)
  • These patients were classified into two groups according to their serum levels of neprilysin and categorized into the lower neprilysin group ( n = 348) and the higher neprilysin group ( n = 346). (biomedcentral.com)
  • Of the 796 eligible patients, 694 had samples available for measurement of serum levels of neprilysin. (biomedcentral.com)
  • however, the relationship between neprilysin expression and carcinogenesis remains obscure. (wikipedia.org)
  • The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure. (bvsalud.org)
  • Unlike other methods designed to lower Abeta levels in blood, which cause a net increase in peptide, neprilysin expression results in the catabolism of Abeta to small, innocuous peptide fragments. (nih.gov)
  • Neprilysin levels were measured in 694 consecutive patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). (biomedcentral.com)
  • Scientific data shows that mammalian neprilysin has several potential peptide targets involved in regulating neuronal function, appetite, metabolism, energy homeostasis and inflammation . (anaspec.com)